Economics of gastroenteropancreatic neuroendocrine tumors : a systematic review
Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid))
Díaz, Ángel (Hospital Clínico San Carlos (Madrid))
López, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Munarriz, Javier (Consorci Hospitalari Provincial de Castelló)
Reina, Juan-José (Hospital Universitario Virgen Macarena (Sevilla, Andalusia))
Vera, Ruth (Complejo Hospitalario de Navarra)
Bernárdez, Beatriz (Complejo Hospitalario Universitario de Santiago de Compostela)
Aller, Javier (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron)
García-Carbonero, Rocío
Jimenez Fonseca, Paula
Trapero-Bertran, Marta (Universitat Internacional de Catalunya)
Universitat Autònoma de Barcelona

Data:	2019
Resum:	Despite current interest, enthusiasm and progress in the development of therapies for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs), there are substantial gaps in the published literature regarding cost-of-illness analyses, economic evaluation and budget impact analyses. Compounding the issue is that data on resource utilization and cost-effectiveness of different diagnostic and therapeutic modalities for GEP-NETs are scarce. A systematic review on the economic impact of GEP-NETs was carried out using four databases: EMBASE, PubMed, the National Health Service Economic Evaluation Database and Cochrane review. Fully published articles from January 2000 to May 2017, in English and Spanish, were included. All articles that satisfied the inclusion criteria were included in the systematic review; summary descriptive statistics were used to describe the methodological characteristics. The 14 studies selected included cost-of-illness analyses (n = 4), economic evaluations (n = 7) and budget impact analyses (n = 3). Almost all studies were performed in the United States. Healthcare costs for patients with NETs included medication, outpatient visits, hospitalizations, and check-ups/tests. Reducing adverse events is an area where cost savings could be achieved; however, there was not enough evidence on the cost impact of adverse events. There is a lack of data related to resource utilization in the field of GEP-NETs. Therefore, cost-effectiveness and budget impact studies of existing and emerging treatments are urgently needed to help the decision-making process for patients with NETs.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Budget impact ; Cost-of-illness ; Costs ; Economic burden ; Economic evaluation ; Gastroenteropancreatic neuroendocrine tumors ; Resource utilization ; Systematic review
Publicat a:	Therapeutic Advances in Endocrinology and Metabolism, Vol. 10 (february 2019) , ISSN 2042-0196

DOI: 10.1177/2042018819828217
PMID: 30815246

12 p, 182.8 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats